DIA415.36+6.58 1.61%
SPX5,638.94+117.42 2.13%
IXIC17,754.09+451.07 2.61%

What's Going On With NRX Pharmaceuticals Stock Tuesday?

Benzinga·01/28/2025 16:44:45
Listen to the news

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are moving higher on Tuesday after it oversaw an investment of $27 million in its subsidiary HOPE Therapeutics.

The Details: The purpose of the investment is to fund a nationwide rollup of Interventional Psychiatry Clinics to treat patients with severe, suicidal depression and PTSD. The clinics will use treatments that combine ketamine and other psychedelic medications with Transcranial Magnetic Stimulation and the recently FDA-approved Digital Therapeutics.

The details of the financing include a $27 million stock purchase agreement between HOPE and Smith and Sauer, LLC. The agreement details an immediate $2 million investment and a commitment to invest $25 million in Series A Preferred Stock by April.

“Today’s transaction caps several months of intensive work as we have identified best-in-class interventional psychiatry clinics and assembled the capital from both Anson Funds and Smith and Sauer to consummate the initial acquisitions,” said Jonathan Javitt, MD MPH Chairman of NRx Pharmaceuticals.

“The resources committed today are anticipated to bring the Company to the $100 million revenue threshold. We have initiated a financial advisory relationship with a leading investment bank to assemble the next $400 million of capital required to build a national and international presence.”

Related Link: Going Underground: Travis Kelce’s “Iceberg House” Is A Subterranean Lair Of Opulence Being Adopted By Many A-Listers

NRXP Price Action: At the time of publication, NRX shares are trading 17.9% higher at $3.36, according to data from Benzinga Pro.

Image: via Shutterstock

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.